Published in Cancer Weekly, September 23rd, 2003
Dr. Robert Milroy, Stobhill Hospital, Glasgow, Scotland, lead investigator of the study, said, "Only NSCLC patients in the study arm receiving early intervention (Hb 12-13 g/dl) with epoetin alfa maintained or increased Hb levels during chemotherapy. It is important that oncologists recognize the benefits of proactive anemia management and optimal Hb...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.